Featured Research Search Results
An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)
Clinicaltrials.gov identifier:
NCT05463796
Prevention
Study for people at risk of cancer, including previvors, survivors and family members
Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT06841354
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
Phase 3
The EASE Study: Helping People with Advanced Cancer Cope with Fear of Cancer Progression
Clinicaltrials.gov identifier:
NCT07636200
Quality of Life
Quality of life study for people with advanced cancer experiencing anxiety
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
Clinicaltrials.gov identifier:
NCT05879926
Treatment
Study for premenopausal, early-stage, ER positive, HER2-negative breast cancer
Phase 3
Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
Clinicaltrials.gov identifier:
NCT05372640
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Phase 1
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT05932862
Treatment
Treatment study for people with advanced solid tumors
Phase 1
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations
Clinicaltrials.gov identifier:
NCT04890613
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Phase 1
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
Clinicaltrials.gov identifier:
NCT06380751
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
Phase 3
Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs
Clinicaltrials.gov identifier:
NCT06167317
Treatment
Treatment study for people with advanced or metastatic solid tumors
Phase 1
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib
Clinicaltrials.gov identifier:
NCT06488378
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Phase 1
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT06401421
Treatment
Biomarker study for people with early-stage breast cancer
Testing a Shorter Course of Chemo- and Immunotherapy for People With Early-Stage Triple-Negative Breast Cancer
Clinicaltrials.gov identifier:
NCT05929768
Treatment
Treatment study for early-stage triple-negative breast cancer
Phase 3
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
Clinicaltrials.gov identifier:
NCT04090567
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
Phase 2
New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT06022029
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
Phase 1
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
Clinicaltrials.gov identifier:
NCT05417594
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
Phase 1/2
WISDOM Study: Women Informed to Screen Depending on Measures of Risk
Clinicaltrials.gov identifier:
NCT02620852
Prevention
Genetic testing and breast cancer screening
Observing People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
Clinicaltrials.gov identifier:
NCT01443468
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)
Clinicaltrials.gov identifier:
NCT03729115
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor